C2N Diagnostics

C2N Diagnostics is a privately held, commercial-stage company providing advanced blood-based biomarker tests for Alzheimer's disease. Its core technology is a proprietary liquid-chromatography-tandem mass spectrometry (LC-MS/MS) platform used to detect amyloid pathology and other biomarkers with high accuracy. The company generates revenue through its CLIA lab services, has established key international partnerships, and plays a significant role in supporting clinical trials for disease-modifying therapies. C2N is positioned at the forefront of the rapidly growing market for accessible, blood-based neurodegenerative disease diagnostics.

Proprietary liquid-chromatography-tandem mass spectrometry (LC-MS/MS) for precise measurement of blood-based protein biomarkers, including amyloid beta ratios, ApoE proteotype, and phosphorylated tau species.

C2N competes in the rapidly evolving blood-based biomarker space for Alzheimer's disease. Key competitors include large clinical labs (Quest Diagnostics, Labcorp) developing their own tests, biotech companies like ALZpath (p-tau217 immunoassay), and pharmaceutical/diagnostics giants like Roche and Eli Lilly. Competition is based on test accuracy, accessibility, cost, reimbursement, and the breadth of biomarker information provided.